[go: up one dir, main page]

MX2021002220A - Forma cristalina de base libre de lorlatinib. - Google Patents

Forma cristalina de base libre de lorlatinib.

Info

Publication number
MX2021002220A
MX2021002220A MX2021002220A MX2021002220A MX2021002220A MX 2021002220 A MX2021002220 A MX 2021002220A MX 2021002220 A MX2021002220 A MX 2021002220A MX 2021002220 A MX2021002220 A MX 2021002220A MX 2021002220 A MX2021002220 A MX 2021002220A
Authority
MX
Mexico
Prior art keywords
free base
crystalline form
lorlatinib free
lorlatinib
relates
Prior art date
Application number
MX2021002220A
Other languages
English (en)
Other versions
MX395263B (es
Inventor
Melissa J Birch
Klimentina Dimitrova Pencheva
Stephen Mark Mcallister
Martin Gregory Rowland
Ian Leonard Smales
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2021002220A publication Critical patent/MX2021002220A/es
Publication of MX395263B publication Critical patent/MX395263B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/65—Raman scattering
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08—Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/087—Structure determination of a chemical compound, e.g. of a biomolecule such as a protein

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta invención se refiere a una forma cristalina de base libre de (10R)-7-amino-12-fluoro-2,10,16-trimetil-15-oxo-10,15,16,17-tetra hidro-2H-8,4-(meteno)pirazolo[4,3-h][2,5,11]benzoxadiazaciclo-tet radecina-3-carbonitrilo (lorlatinib) (Forma 7); esta invención se refiere también a composiciones farmacéuticas que comprenden la Forma 7, y a los métodos de uso de la Forma 7 y dichas composiciones en el tratamiento de crecimiento celular anormal, como el cáncer, en un mamífero.
MX2021002220A 2015-07-31 2016-07-27 Forma cristalina de base libre de lorlatinib MX395263B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562199418P 2015-07-31 2015-07-31
US201662352349P 2016-06-20 2016-06-20
PCT/IB2016/054483 WO2017021823A1 (en) 2015-07-31 2016-07-27 Crystalline form of lorlatinib free base

Publications (2)

Publication Number Publication Date
MX2021002220A true MX2021002220A (es) 2022-09-01
MX395263B MX395263B (es) 2025-03-25

Family

ID=56686850

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018001324A MX382600B (es) 2015-07-31 2016-07-27 Forma cristalina de base libre de lorlatinib.
MX2021002220A MX395263B (es) 2015-07-31 2016-07-27 Forma cristalina de base libre de lorlatinib

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018001324A MX382600B (es) 2015-07-31 2016-07-27 Forma cristalina de base libre de lorlatinib.

Country Status (22)

Country Link
US (2) US10420749B2 (es)
EP (2) EP3328867B9 (es)
JP (1) JP6218253B2 (es)
KR (1) KR102088188B1 (es)
CN (3) CN116063322A (es)
AU (1) AU2016304420B2 (es)
BR (1) BR112017028604A2 (es)
CA (1) CA2937257C (es)
CY (1) CY1123689T1 (es)
DK (2) DK3328867T3 (es)
ES (2) ES2842302T3 (es)
FI (1) FI3798222T3 (es)
HK (1) HK1252845A1 (es)
HU (2) HUE052790T2 (es)
MX (2) MX382600B (es)
PL (2) PL3798222T3 (es)
PT (2) PT3328867T (es)
RU (1) RU2018101363A (es)
SG (1) SG10201913200XA (es)
SI (2) SI3798222T1 (es)
TW (1) TWI616449B (es)
WO (1) WO2017021823A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6783311B2 (ja) 2015-09-24 2020-11-11 サイクレニウム ファーマ インコーポレーテッド ヘテロアリール含有大環状化合物のライブラリならびにその製造方法および使用方法
US11078215B2 (en) 2016-04-08 2021-08-03 Pfizer Inc. Crystalline forms of lorlatinib maleate
EP3642399A4 (en) * 2017-06-22 2020-10-14 Cyclenium Pharma Inc. LIBRARIES OF MACROCYCLIC COMPOUNDS CONTAINING PYRIDINE AND THEIR PREPARATION AND USE PROCEDURES
HUE062926T2 (hu) * 2017-10-10 2023-12-28 Pfizer Lorlatinib mint szabad bázis hidrátjának kristályos formája
US11179412B2 (en) 2017-12-04 2021-11-23 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating conditions involving elevated inflammatory response
EP3784675A1 (en) 2018-04-23 2021-03-03 Pliva Hrvatska D.O.O. Solid state forms of lorlatinib and their preparation
CN109232607A (zh) * 2018-09-20 2019-01-18 沈阳药科大学 劳拉替尼的合成方法
KR20210114996A (ko) * 2019-01-17 2021-09-24 화이자 인코포레이티드 Cdk 억제제의 결정질 형태
WO2021011345A1 (en) * 2019-07-18 2021-01-21 Pliva Hrvatska D.O.O Crystalline lorlatinib : fumaric acid and solid state form thereof
CN110483551B (zh) * 2019-08-30 2021-10-22 北京赛思源生物医药技术有限公司 一种劳拉替尼游离碱的晶体
CN110530998A (zh) * 2019-09-16 2019-12-03 山东省药学科学院 一种劳拉替尼及含劳拉替尼的制剂中有关物质的检测方法
EP4041396A1 (en) 2019-10-10 2022-08-17 Sandoz AG Polymorph of lorlatinib
CN112824417A (zh) * 2019-11-21 2021-05-21 上海天慈国际药业有限公司 一种劳拉替尼的制备方法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2566858A2 (en) 2010-05-04 2013-03-13 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2643314B1 (en) * 2010-11-25 2016-07-13 ratiopharm GmbH Novel salts and polymorphic forms of afatinib
CN104169286B (zh) * 2012-03-06 2016-06-08 辉瑞大药厂 用于治疗增殖性疾病的大环衍生物
US9637500B2 (en) 2013-06-28 2017-05-02 Pfizer Inc. Solid forms of a macrocyclic kinase inhibitor
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
US11078215B2 (en) 2016-04-08 2021-08-03 Pfizer Inc. Crystalline forms of lorlatinib maleate
HUE062926T2 (hu) 2017-10-10 2023-12-28 Pfizer Lorlatinib mint szabad bázis hidrátjának kristályos formája

Also Published As

Publication number Publication date
NZ739304A (en) 2024-11-29
FI3798222T3 (fi) 2023-11-28
PT3798222T (pt) 2024-01-22
SG10201913200XA (en) 2020-03-30
EP3328867B1 (en) 2020-11-11
PL3798222T3 (pl) 2024-03-25
EP3798222B1 (en) 2023-11-22
US11020376B2 (en) 2021-06-01
EP3798222A1 (en) 2021-03-31
MX2018001324A (es) 2018-04-30
MX382600B (es) 2025-03-13
PT3328867T (pt) 2021-01-13
WO2017021823A1 (en) 2017-02-09
BR112017028604A2 (pt) 2018-09-04
US10420749B2 (en) 2019-09-24
SI3798222T1 (sl) 2024-02-29
HUE052790T2 (hu) 2021-05-28
CY1123689T1 (el) 2022-03-24
KR102088188B1 (ko) 2020-03-12
JP6218253B2 (ja) 2017-10-25
AU2016304420B2 (en) 2019-09-19
US20180235933A1 (en) 2018-08-23
DK3328867T3 (da) 2020-11-16
HK1252845A1 (zh) 2019-06-06
HUE065536T2 (hu) 2024-05-28
SI3328867T1 (sl) 2021-04-30
TWI616449B (zh) 2018-03-01
AU2016304420A1 (en) 2018-02-01
CA2937257C (en) 2022-06-14
CN107849060A (zh) 2018-03-27
RU2018101363A (ru) 2019-08-29
MX395263B (es) 2025-03-25
US20190365712A1 (en) 2019-12-05
ES2972010T3 (es) 2024-06-10
TW201718600A (zh) 2017-06-01
DK3798222T3 (da) 2023-12-11
EP3328867A1 (en) 2018-06-06
JP2017039702A (ja) 2017-02-23
ES2842302T3 (es) 2021-07-13
CN116063322A (zh) 2023-05-05
CN116063323A (zh) 2023-05-05
EP3328867B9 (en) 2021-04-14
CA2937257A1 (en) 2017-01-31
PL3328867T3 (pl) 2021-04-19
KR20180022936A (ko) 2018-03-06
RU2018101363A3 (es) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2021002220A (es) Forma cristalina de base libre de lorlatinib.
MX2017014809A (es) Amidas heterociclicas como inhibidores de cinasa.
CL2018003474A1 (es) Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen.
UY34220A (es) Indazoles, composiciones farmacéuticas y uso de los mismos
CO2017001994A2 (es) Compuestos activos hacia bromodominios
UY34669A (es) COMPUESTOS EN BASE A IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y MÉTODOS PARA SU USO.
MX2017004906A (es) Dihidropirrolopiridinas inhibidoras del receptor huerfano-gamma.
CR20150524A (es) Compuestos de heteroarilo y sus usos
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY34536A (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos
EA201691194A1 (ru) Стимуляторы ргц
CO2017002160A2 (es) Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2015002304A1 (es) Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato
CL2013002650A1 (es) Compuestos derivados triciclicos con actividad sobre los receptores hormonales nucleares; composicion farmaceutica que los comprende; proceso de reparacion de compuestos intermediarios; y uso en el tratamiento del sida, insuficiencia adrenal aguda, enfermedad de addison, rinitis alergica, enfermedad de alzheimer, entre otros.
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
MX391724B (es) Nuevos derivados de triazolo[4,5-d]pirimidina.
CY1126141T1 (el) Κρυσταλλικη μορφη του υδριτη ελευθερης βασης λορλατινιμπης
MX2018004664A (es) Antagonistas de ep4.
ECSP16074478A (es) Compuestos novedosos